6 suspended. 6 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Suspended 6 |
| Phase 1 | 2 | Suspended 2 |
| Phase 3 | 2 | Suspended 2 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Suspended | Shandong Cancer Hospital and Institute | 184 | 2025-11-30 | 2026-10-15 |
| Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma Adebrelimab - Adebrelimab, Hepatocellular Carcinoma | Phase 2 | Suspended | Tianjin Medical University Cancer Institute and Hospital | 40 | 2024-05-01 | 2026-05-29 |
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC Nivolumab and TACE/TAE, TACE/TAE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | The Clatterbridge Cancer Centre NHS Foundation Trust | 522 | 2019-05-08 | 2025-02-26 |
| Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Suspended | HRYZ Biotech Co. | 100 | 2013-07-01 | 2017-10-18 |
| Mesenchymal Stem Cells Treat Liver Cirrhosis Conserved Therapy, Hepatic artery infusion or Intravenous infusion - Liver Cirrhosis | Phase 1 / Phase 2 | Suspended | Yufang Shi | 200 | 2009-10-01 | 2016-02-22 |
Carcinoma, Hepatocellular (5) · Liver Cirrhosis (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1)
Digestive System Diseases (6) · Adenocarcinoma (5) · Carcinoma (5) · Digestive System Neoplasms (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Liver Neoplasms (4) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Fibrosis (1) · Neoplastic Processes (1)
Bevacizumab (1) · Folfox protocol (1) · Infusions, Intravenous (1) · Nivolumab (1) · Radiotherapy (1) · Sorafenib (1) · lenvatinib (1)
HRYZ Biotech Co. (1) · Mirror Biologics, Inc. (1) · Shandong Cancer Hospital and Institute (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yufang Shi (1)
China (4) · France (1) · Malaysia (1) · Thailand (1) · United Kingdom (1)
Daniel Palmer, PhD, MD (1) · Jianhe Gan, MD (1) · Yufang Shi, PhD,DVM (1)